Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–95 of 95 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: norgestrel Clear all

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 532 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 14 more

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Hormonal Contraception
Interventions: Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Healthy Participants
Interventions: Elenestinib, Midazolam, Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG); Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Menstruation Disturbances, Premenstrual Syndrome
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 69
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more

Conditions: Healthy
Interventions: AZD6140, Levonorgestrel and Ethinyl Estradiol (Nordette®); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Contraception
Interventions: Placebo Control (Placebo Herb), St. John's Wort, Levonorgestrel; Dietary Supplement · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Menopausal and Other Perimenopausal Disorders
Interventions: Mirena, Estradiol, Placebo Gel; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 52 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Bariatric Surgery Candidate, Contraception
Interventions: ethinyl estradiol-levonorgestrel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pregnancy
Interventions: Mirena (Levonorgestrel IUS, BAY86-5028), ParaGard, Implanon/Nexplanon; Drug
Lead sponsor: Bayer; Industry
Eligibility: 15 Years to 44 Years · Female only
Enrollment: 13,880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Temporomandibular Joint Disorders
Interventions: Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions: Mirena, Oral contraception, Depo-Provera; Drug
Lead sponsor: Thomas Cherpes, DVM, MD; Other
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Contraception, Malposition of Intrauterine Contraceptive Device
Interventions: Levonorgestrel Intrauterine System (LNG-IUS); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy, Men, Male Contraception
Interventions: Dimethandrolone-Undecanoate, Levonorgestrel 0.03 MG, Placebo oral capsule; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Contraception
Interventions: Levonorgestrel (BAY98-7196); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 1,471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 79
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 67 more

Conditions: Contraception
Interventions: Paragard, Mirena; Device · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Contraception
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 49
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more

Conditions: Contraception
Interventions: Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 28
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more

Conditions: Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Interventions: combined oral contraceptives; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 64 participants
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Female Volunteers
Interventions: PF-06700841, Ethinyl estradiol (EE) and levonorgestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: Contraception
Interventions: DR-1011; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 2,235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 55
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Contraception
Interventions: LNG20, Mirena; Drug
Lead sponsor: Medicines360; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 1,910 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 25
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more

Search by objective public record fields.

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

Contraceptive Hormones, Immunity, and Microbiome Evaluation

A Study of Elenestinib in Healthy Adult Female Participants

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

AZD6140 Oral Contraceptive Interaction Study

Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

Duration of Use of Highly Effective Reversible Contraception

Managing Temporomandibular Disorder (TMD) Symptoms

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

LNG-IUS at 2 Weeks Postpartum

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women

Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study

Mirena Extension Trial

US Cycle Control and Blood Pressure Study

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception